查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1803145

全球迷幻微劑量市場：2032 年預測 - 按成分、給藥途徑、分銷管道、應用和地區進行分析

Psychedelic Microdosing Market Forecasts to 2032 - Global Analysis By Component (Psilocybin, Ketamine, MDMA and Other Compounds), Route of Administration, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球迷幻微劑量市場預計在 2025 年達到 21 億美元，到 2032 年將達到 58 億美元，預測期內的複合年成長率為 15%。

迷幻微劑量是指攝取極少量、低於感知劑量的迷幻物質，例如LSD或裸蓋菇素，通常為娛樂劑量的十分之一到二十分之一。與產生幻覺或強烈感知改變的完全迷幻體驗不同，微劑量旨在產生微妙的認知、情緒和生理益處，而不會顯著損害日常功能。支持者指出，微劑量可以增強創造力、專注力、情緒穩定性和情緒健康，同時還可以減輕焦慮和憂鬱症狀。雖然其潛在的心理健康和生產力益處使其越來越受歡迎，但關於其安全性、有效性和長期影響的科學研究仍然有限且仍在進行中。

對新型心理健康治療的需求不斷成長

憂鬱症、焦慮症和創傷後壓力症候群（PTSD）的盛行率不斷上升，暴露了傳統治療方法的不足。迷幻藥微劑量因其能夠改善情緒、增強注意力、促進心理健康，同時最大程度地減少副作用而備受關注。公眾意識的不斷提升，加上積極的臨床觀察，正在提高患者和醫療保健相關人員對迷幻藥的接受度。這種勢頭正在推動對安全、受監管的迷幻療法開發的投資，從而使迷幻藥市場迅速擴張，應用範圍也更加廣泛。

關於微劑量的高品質臨床證據有限

由於缺乏強力的臨床試驗，監管機構對核准或支持微劑量療法持謹慎態度。缺乏檢驗也降低了投資者信心，並限制了研究和商業化的資金投入。有限的科學證據進一步阻礙了醫療保健專業人員推薦微劑量療法。因此，消費者的接受速度緩慢，且主要受傳聞經驗而非臨床檢驗的影響。最終，缺乏可靠的證據阻礙了市場擴張，並延遲了更廣泛的接受度。

新的產品形式和分銷管道

膠囊、軟糖、鼻噴霧和舌下含片等創新產品形式，實現了便捷精準的給藥。這些形式使微劑量給藥更加便捷，減少污名化，進而吸引更廣泛的消費者群體。線上平台、遠端醫療服務和健康診所透過提供謹慎安全的途徑，進一步加強了分銷。零售合作夥伴關係和數位市場也有助於提高認知度和消費者信任度。這些進步將共同推動微劑量給藥的廣泛應用和市場成長。

法規和法律障礙

許多國家嚴格的藥品分類法限制了迷幻藥的研究、臨床試驗和治療應用。冗長的核准流程和複雜的合規要求阻礙了新參與企業的創新和市場准入。缺乏統一的全球法規進一步限制了跨國合作與擴張。對法律影響的擔憂阻礙了該領域的投資和業務發展。總體而言，這些障礙減緩了該領域的應用，並限制了市場的成長潛力。

COVID-19的影響

新冠疫情對迷幻微劑量市場產生了多重影響。一方面，它限制了臨床試驗和研究，延緩了產品開發和監管進程。供應鏈中斷也影響了原料的取得和迷幻產品的供應。然而，疫情也加劇了焦慮、憂鬱症和壓力等心理健康挑戰，導致人們對微劑量等替代療法的興趣日益濃厚。在此期間，遠端醫療和數位心理健康平台的普及進一步提升了人們對迷幻微劑量的認知和討論。

預計在預測期內，裸蓋菇素類藥物的市佔率將達到最大

由於裸蓋菇素在心理健康研究和治療領域的接受度不斷提高，預計將在預測期內佔據最大的市場佔有率。越來越多的臨床研究強調了裸蓋菇素在治療憂鬱症、焦慮症和創傷後壓力症候群方面的有效性，這推動了對可控微劑量的需求。社會意識的增強和對天然迷幻藥的污名化減少進一步推動了其應用。此外，一些地區的監管機構正在放寬監管，為裸蓋菇素的商業性應用開闢了機會。總體而言，裸蓋菇素強大的治療潛力和不斷變化的認知是市場成長的關鍵驅動力。

預計認知增強領域在預測期內將以最高的複合年成長率成長。

預計認知增強領域將在預測期內實現最高成長率，吸引那些尋求提升專注力、創造力和生產力的人。專業人士、學生和企業家日益成長的興趣正在推動需求成長，因為微劑量如今被視為最佳化心理表現的工具。科學研究和傳聞證據強調了其在提高問題解決能力和記憶力等方面的益處，這進一步增強了市場接受度。精神活性藥物與健康趨勢的日益融合也使微劑量成為主流。整體而言，認知增強正成為關鍵促進因素，將微劑量定位為一種提升表現的生活方式選擇。

比最大的地區

在預測期內，北美預計將佔據最大的市場佔有率，這得益於人們對心理健康的認知不斷提高以及社會對替代療法的態度轉變。對研究、臨床試驗和新興企業系統的持續投資正在加速產品創新和發展。公眾對健康和個人生產力的關注進一步刺激了需求。美國某些州和加拿大地區推出了支持性舉措，推動法規的逐步轉變，創造出更開放的環境。然而，儘管消費者的興趣和機構支持繼續推動市場成長，但法律的不確定性和污名化仍然是挑戰。

複合年成長率最高的地區：

預計歐洲將在預測期內實現最高的複合年成長率，這得益於健康社區、心理健康專業人士和研究機構的濃厚興趣。人們對焦慮、憂鬱症和認知能力替代療法的認知日益提高，這正在塑造需求。各國的法規各不相同，既創造了機遇，也帶來了障礙。學術研究和臨床試驗增強了可信度，而健康旅遊和生活方式趨勢也激發了人們的好奇心。文化對整體健康實踐的接受度也在推動其應用，儘管一些國家的限制性法律體制阻礙了其更廣泛的商業化。

免費客製化服務

此報告的訂閱者可以從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 簡介

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 主要研究資料
    • 二手研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 市場機會
  • 威脅
  • 應用分析
  • 新興市場
  • COVID-19的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 企業之間的競爭

5. 全球迷幻微劑量市場（依成分）

  • 裸蓋菇素
  • LSD
  • 氯胺酮
  • MDMA
  • 其他化合物

6. 全球迷幻微劑量市場（依給藥途徑）

  • 口服
  • 舌下
  • 鼻腔
  • 經皮
  • 其他給藥途徑

7. 全球迷幻微劑量市場（依通路）

  • 處方箋
  • 直接面對消費者
  • 研究用品

8. 全球迷幻微劑量市場（依應用）

  • 心理健康
  • 認知功能增強
  • 健康與生活方式
  • 成癮治療
  • 家庭使用
  • 其他用途

9. 全球迷幻微劑量市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併與收購（M&A）
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • COMPASS Pathways
  • MindMed Inc.
  • Cybin Inc.
  • Atai Life Sciences
  • Beckley Psytech
  • Seelos Therapeutics
  • Delix Therapeutics
  • Eleusis
  • GH Research PLC
  • Awakn Life Sciences
  • Numinus Wellness
  • Mydecine Innovations Group
  • Entheon Biomedical
  • Wesana Health
  • Tryp Therapeutics
  • Enveric Biosciences
  • Clairvoyant Therapeutics
Product Code: SMRC30670

According to Stratistics MRC, the Global Psychedelic Microdosing Market is accounted for $2.1 billion in 2025 and is expected to reach $5.8 billion by 2032 growing at a CAGR of 15% during the forecast period. Psychedelic microdosing refers to the practice of consuming very small, sub-perceptual doses of psychedelic substances such as LSD or psilocybin, typically around one-tenth to one-twentieth of a recreational dose. Unlike full psychedelic experiences that cause hallucinations and intense alterations in perception, microdosing aims to deliver subtle cognitive, emotional, and physiological benefits without significantly impairing daily functioning. Advocates suggest that microdosing may enhance creativity, focus, mood stability, and emotional well-being, while reducing anxiety or depression symptoms. Although gaining popularity for potential mental health and productivity benefits, scientific research on its safety, efficacy, and long-term effects remains limited and ongoing.

Market Dynamics:

Driver:

Rising demand for new mental-health treatments

The rising prevalence of depression, anxiety, and PTSD has exposed the shortcomings of conventional treatments. Microdosing psychedelics is gaining attention for its ability to elevate mood, sharpen focus, and promote mental well-being with reduced adverse effects. Increasing public awareness combined with positive clinical findings is fostering greater acceptance among both patients and medical professionals. This momentum is driving investments in the development of safe, regulated psychedelic therapies. Consequently, the market is experiencing rapid expansion and wider utilization.

Restraint:

Limited high-quality clinical evidence for microdosing

Lack of robust clinical trials makes regulatory authorities cautious about granting approval or support for microdosing. Insufficient validation also diminishes investor trust and limits financial backing for research and commercialization. Limited scientific proof further discourages healthcare professionals from recommending its use. Consumer adoption therefore remains slow and is primarily shaped by anecdotal experiences rather than clinical validation. In turn, the shortage of reliable evidence hinders market expansion and delays wider acceptance.

Opportunity:

New product formats & distribution channels

Innovative product forms such as capsules, gummies, nasal sprays, and sublingual strips offer convenient and precise dosing. These formats appeal to a wider consumer base by making microdosing more approachable and less stigmatized. Online platforms, telehealth services, and wellness clinics further enhance distribution by providing discreet and safe access. Retail partnerships and digital marketplaces also help increase visibility and consumer trust. Together, these advancements drive broader adoption and market growth.

Threat:

Regulatory & legal barriers

Strict drug classification laws in many countries restrict research, clinical trials, and therapeutic applications of psychedelics. Lengthy approval processes and complex compliance requirements slow down innovation and market entry for new players. The lack of harmonized global regulations further limits cross-border collaboration and expansion. Fear of legal repercussions discourages investment and business development in the sector. Overall, these barriers delay adoption and restrict the market's growth potential.

Covid-19 Impact

The Covid-19 pandemic had a mixed impact on the psychedelic microdosing market. On one hand, restrictions on clinical trials and research slowed product development and regulatory progress. Supply chain disruptions also affected access to raw materials and delivery of psychedelic-based products. However, the pandemic increased mental health challenges such as anxiety, depression, and stress, leading to growing interest in alternative therapies like microdosing. The shift toward telemedicine and digital mental health platforms further supported awareness and discussions around psychedelic microdosing during this period.

The psilocybin segment is expected to be the largest during the forecast period

The psilocybin segment is expected to account for the largest market share during the forecast period, due to its growing acceptance in mental health research and therapy. Increasing clinical studies highlight psilocybin's effectiveness in treating depression, anxiety, and PTSD, driving demand for controlled microdosing. Rising public awareness and reduced stigma around natural psychedelics further encourage adoption. Additionally, regulatory bodies in some regions are easing restrictions, opening opportunities for commercial applications. Overall, psilocybin's strong therapeutic potential and shifting perceptions make it a key growth driver for the market.

The cognitive enhancement segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cognitive enhancement segment is predicted to witness the highest growth rate by attracting individuals seeking improved focus, creativity, and productivity. Rising interest from professionals, students, and entrepreneurs fuels demand as microdosing is increasingly viewed as a tool for mental performance optimization. Scientific studies and anecdotal evidence highlighting benefits like better problem-solving and memory retention further strengthen market adoption. The growing integration of nootropics and wellness trends also aligns with the microdosing movement, making it more mainstream. Overall, cognitive enhancement acts as a key driver by positioning microdosing as a performance-boosting lifestyle choice.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to rising mental health awareness and shifting societal attitudes toward alternative therapies. Increasing investment in research, clinical trials, and startup ecosystems is accelerating product innovation and development. Public discourse around wellness and personal productivity further strengthens demand. Supportive initiatives in certain U.S. states and Canadian regions foster progressive regulatory shifts, creating a more open environment. However, legal uncertainties and stigma remain challenges, though consumer interest and institutional backing continue to push market growth.

Region with highest CAGR:

Over the forecast period, the Europe region is anticipated to exhibit the highest CAGR, owing to strong interest from wellness communities, mental health practitioners, and research organizations. Growing awareness of alternative treatments for anxiety, depression, and cognitive performance is shaping demand. Regulations are mixed across countries, creating both opportunities and barriers. Academic studies and clinical trials drive credibility, while wellness tourism and lifestyle trends also fuel curiosity. The cultural acceptance of holistic health practices supports adoption, though stricter legal frameworks in several nations slow down wider commercialization.

Key players in the market

Some of the key players profiled in the Psychedelic Microdosing Market include COMPASS Pathways, MindMed Inc., Cybin Inc., Atai Life Sciences, Beckley Psytech, Seelos Therapeutics, Delix Therapeutics, Eleusis, GH Research PLC, Awakn Life Sciences, Numinus Wellness, Mydecine Innovations Group, Entheon Biomedical, Wesana Health, Tryp Therapeutics, Enveric Biosciences, and Clairvoyant Therapeutics.

Key Developments:

In April 2025, Cybin secured Strategic Partnership Agreements with 18 clinical sites for its Phase 3 CYB003 program. These collaborations aim to streamline operations, boost patient recruitment, and standardize protocols across the PARADIGM trial's multinational infrastructure.

In February 2024, MindMed partnered with Sphere Health to advance digital biomarkers and remote monitoring for psychedelic therapies, including microdosing. The collaboration integrates wearable tech with clinical protocols to enhance patient tracking, dose-response analysis, and personalized treatment optimization.

In January 2024, COMPASS entered a three-year research collaboration with Greenbrook TMS to pilot COMP360 psilocybin therapy across U.S. clinics. The initiative targets treatment-resistant depression, optimizing therapist workflows, patient experience, and digital integration for scalable delivery.

Compounds Covered:

  • Psilocybin
  • LSD
  • Ketamine
  • MDMA
  • Other Compounds

Route of Administrations Covered:

  • Oral
  • Sublingual
  • Nasal
  • Transdermal
  • Other Route of Administrations

Distribution Channels Covered:

  • Prescription
  • Direct-to-consumer
  • Research supply

Applications Covered:

  • Mental health
  • Cognitive enhancement
  • Wellness and lifestyle
  • Addiction treatment
  • Home use
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Psychedelic Microdosing Market, By Compound

  • 5.1 Introduction
  • 5.2 Psilocybin
  • 5.3 LSD
  • 5.4 Ketamine
  • 5.5 MDMA
  • 5.6 Other Compounds

6 Global Psychedelic Microdosing Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Sublingual
  • 6.4 Nasal
  • 6.5 Transdermal
  • 6.6 Other Route of Administrations

7 Global Psychedelic Microdosing Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Prescription
  • 7.3 Direct-to-consumer
  • 7.4 Research supply

8 Global Psychedelic Microdosing Market, By Application

  • 8.1 Introduction
  • 8.2 Mental health
  • 8.3 Cognitive enhancement
  • 8.4 Wellness and lifestyle
  • 8.5 Addiction treatment
  • 8.6 Home use
  • 8.7 Other Applications

9 Global Psychedelic Microdosing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 COMPASS Pathways
  • 11.2 MindMed Inc.
  • 11.3 Cybin Inc.
  • 11.4 Atai Life Sciences
  • 11.5 Beckley Psytech
  • 11.6 Seelos Therapeutics
  • 11.7 Delix Therapeutics
  • 11.8 Eleusis
  • 11.9 GH Research PLC
  • 11.10 Awakn Life Sciences
  • 11.11 Numinus Wellness
  • 11.12 Mydecine Innovations Group
  • 11.13 Entheon Biomedical
  • 11.14 Wesana Health
  • 11.15 Tryp Therapeutics
  • 11.16 Enveric Biosciences
  • 11.17 Clairvoyant Therapeutics

List of Tables

  • Table 1 Global Psychedelic Microdosing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 3 Global Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 4 Global Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 5 Global Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 6 Global Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 7 Global Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 8 Global Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 9 Global Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 10 Global Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 11 Global Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 12 Global Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 13 Global Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 14 Global Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 15 Global Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 16 Global Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 17 Global Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 18 Global Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 19 Global Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 20 Global Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 21 Global Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 22 Global Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 23 Global Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 24 Global Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 25 North America Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
  • Table 26 North America Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 27 North America Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 28 North America Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 29 North America Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 30 North America Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 31 North America Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 32 North America Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 33 North America Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 34 North America Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 35 North America Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 36 North America Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 37 North America Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 38 North America Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 39 North America Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 40 North America Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 41 North America Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 42 North America Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 43 North America Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 44 North America Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 45 North America Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 46 North America Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 47 North America Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 48 North America Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 49 Europe Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
  • Table 50 Europe Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 51 Europe Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 52 Europe Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 53 Europe Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 54 Europe Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 55 Europe Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 56 Europe Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 57 Europe Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 58 Europe Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 59 Europe Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 60 Europe Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 61 Europe Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 62 Europe Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 63 Europe Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 64 Europe Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 65 Europe Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 66 Europe Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 67 Europe Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 68 Europe Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 69 Europe Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 70 Europe Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 71 Europe Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 72 Europe Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 73 Asia Pacific Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
  • Table 74 Asia Pacific Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 75 Asia Pacific Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 76 Asia Pacific Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 77 Asia Pacific Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 78 Asia Pacific Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 79 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 80 Asia Pacific Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 81 Asia Pacific Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 82 Asia Pacific Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 83 Asia Pacific Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 84 Asia Pacific Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 85 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 86 Asia Pacific Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 87 Asia Pacific Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 88 Asia Pacific Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 89 Asia Pacific Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 90 Asia Pacific Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 91 Asia Pacific Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 92 Asia Pacific Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 93 Asia Pacific Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 94 Asia Pacific Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 95 Asia Pacific Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 96 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 97 South America Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
  • Table 98 South America Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 99 South America Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 100 South America Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 101 South America Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 102 South America Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 103 South America Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 104 South America Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 105 South America Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 106 South America Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 107 South America Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 108 South America Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 109 South America Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 110 South America Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 111 South America Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 112 South America Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 113 South America Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 114 South America Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 115 South America Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 116 South America Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 117 South America Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 118 South America Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 119 South America Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 120 South America Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 121 Middle East & Africa Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
  • Table 122 Middle East & Africa Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 123 Middle East & Africa Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 124 Middle East & Africa Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 125 Middle East & Africa Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 126 Middle East & Africa Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 127 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 128 Middle East & Africa Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 129 Middle East & Africa Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 130 Middle East & Africa Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 131 Middle East & Africa Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 132 Middle East & Africa Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 133 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 134 Middle East & Africa Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 135 Middle East & Africa Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 136 Middle East & Africa Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 137 Middle East & Africa Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 138 Middle East & Africa Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 139 Middle East & Africa Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 140 Middle East & Africa Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 141 Middle East & Africa Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 142 Middle East & Africa Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 143 Middle East & Africa Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 144 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)